Overview

The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects

Status:
Completed
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
This is a Single Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled Phaseâ… Clinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics with A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects. The primary objective of this study is to investigate the safety and tolerability of a range of subcutaneous SHR-1222 in healthy subjects. Secondary objectives are to determine the pharmacokinetics (PK) and pharmacodynamics(PD) profile of SHR-1222 in healthy subjects including assessment of immunogenicity.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.